• Phillygenin Attenuates Diabetic Nephropathy via TLR4 and PI3

  2026-05-24

  This study demonstrates that phillygenin, a Forsythia suspensa-derived compound, alleviates diabetic nephropathy by inhibiting kidney inflammation and apoptosis through the TLR4/MyD88/NF-κB and PI3K/AKT/GSK3β signaling pathways. These findings provide mechanistic insight into phillygenin's renal protective effects and highlight new avenues for therapeutic intervention in diabetic kidney disease.

• Balsalazide Disodium: Targeted 5-ASA Delivery for Ulcerative

  2026-05-23

  The reference study introduces balsalazide disodium as a novel 5-aminosalicylate (5-ASA) prodrug designed for efficient, colon-targeted release of active 5-ASA via bacterial azoreduction. Its improved induction of remission and favorable safety profile in mild-to-moderate ulcerative colitis signal important advances for research and clinical modeling of inflammatory bowel disease.

• Cardiovascular Outcomes With Ertugliflozin in Type 2 Diabete

  2026-05-22

  The VERTIS CV trial rigorously evaluated the long-term cardiovascular safety of ertugliflozin in patients with type 2 diabetes and established atherosclerotic cardiovascular disease. Results showed that ertugliflozin was noninferior to placebo for major adverse cardiovascular events, with modest signals for heart failure and renal outcomes. These findings provide a key reference point for designing translational cardiovascular and hypertension research models, informing the integration of established agents such as ACE inhibitors.

• Radicicol: Mechanistic Leverage for Translational Metabolic

  2026-05-22

  This thought-leadership article explores Radicicol’s multifaceted role as an Hsp90 and PDK3 inhibitor, detailing its mechanistic actions, experimental workflows, and translational potential in adipogenesis, apoptosis, and inflammation. Emphasizing recent evidence and protocol insights, the article positions APExBIO’s Radicicol as a precision tool for metabolic, cancer, and inflammation research, with direct guidance for translational investigators.

• GPR107 Deficiency Drives Diabetic Nephropathy via AT1R Pathw

  2026-05-21

  Xu et al. reveal that loss of G protein‐coupled receptor 107 (GPR107) exacerbates diabetic nephropathy by impairing angiotensin II receptor type 1 (AT1R) internalization in podocytes, resulting in excess collagen IV accumulation and glomerular basement membrane thickening. These findings clarify a mechanistic link between podocyte endocytosis dysfunction and fibrosis in diabetic kidney disease, suggesting new pathways for therapeutic targeting.

• ATRX-Deficient Glioma Cells: Enhanced Sensitivity to RTK Inh

  2026-05-21

  The reference study identifies that high-grade glioma cells lacking ATRX are more vulnerable to multi-targeted receptor tyrosine kinase (RTK) and PDGFR inhibitors. This finding suggests that ATRX mutation status may be a key factor for optimizing targeted therapy strategies in aggressive gliomas.

• Calcium Carbonate Nanoparticle-Mediated IL-12 mRNA Delivery

  2026-05-20

  Zhao et al. developed a biomimetic calcium carbonate nanoparticle platform capable of delivering IL-12 mRNA across the blood-brain barrier to target glioblastoma, activating antitumor immunity via ultrasound-induced necroptosis. Their approach demonstrates effective BBB penetration, tumor specificity, and immune activation, presenting a promising strategy for overcoming key limitations in brain tumor immunotherapy.

• ALT Cancer Cells and ATR Inhibition: Insights from Viability

  2026-05-20

  This article examines the pivotal study by Deeg et al., which challenges the widely held assumption that cancer cells using alternative lengthening of telomeres (ALT) are generally hypersensitive to ATR inhibition. The findings have direct implications for the design of viability and apoptosis assays in oncology research, particularly regarding the interpretation of DNA intercalating dye-based measurements.

• Imidazoline Antagonists Boost Insulin via K+ Channel Blockad

  2026-05-19

  This study demonstrates that imidazoline antagonists of α2-adrenoceptors elevate insulin secretion in vitro by directly inhibiting ATP-sensitive potassium channels in pancreatic β-cells, rather than by adrenoceptor blockade. These findings provide mechanistic clarity for insulinotropic drug actions and inform the design of metabolic and electrophysiological research workflows.

• Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe): Technical

  2026-05-19

  Angiotensin II enables precise modeling of hypertension mechanisms, cardiovascular remodeling, and vascular smooth muscle cell hypertrophy in both in vitro and in vivo research settings. This technical guide outlines actionable protocols, storage, and workflow controls for reproducible experimental outcomes. It is not intended for diagnostic or clinical use.

• T-5224 (C-Fos/AP-1 Inhibitor): Optimized Workflows in Inflam

  2026-05-18

  T-5224, a selective C-Fos/AP-1 inhibitor from APExBIO, empowers researchers to dissect neuroinflammatory and osteoclastogenic pathways with unprecedented specificity. This article translates recent scientific breakthroughs into practical assay enhancements, protocol parameters, and troubleshooting insights for inflammation and arthritis research.

• Resazurin Sodium Salt: Optimizing Viability Assays for Preci

  2026-05-18

  Explore how Resazurin sodium salt, a leading fluorogenic oxidation-reduction indicator, enables nuanced and reproducible cell viability assessment in advanced models—offering unique protocol guidance, critical evaluation, and translational insight beyond standard workflows.

• Prednisolone (SKU B2012): Reliable Glucocorticoid for Cell A

  2026-05-17

  This article provides an evidence-based, scenario-driven guide to using Prednisolone (SKU B2012) from APExBIO for reproducible cell viability, proliferation, and cytotoxicity assays. Drawing on recent literature and practical laboratory experience, we address common challenges in glucocorticoid signaling research and outline validated protocols for optimal experimental outcomes.

• 25-Hydroxycholesterol Drives Immunosuppressive Macrophage Re

  2026-05-16

  Xiao et al. (2024) reveal that lysosomal accumulation of 25-hydroxycholesterol in tumor-associated macrophages activates AMPKα through the GPR155-mTORC1 axis, leading to enhanced STAT6 signaling and immunosuppressive function. Their findings establish CH25H as a metabolic checkpoint in the tumor microenvironment, with implications for improving immunotherapy efficacy.

• Wortmannin as an Irreversible PI3K Inhibitor: Mechanisms and

  2026-05-15

  Explore Wortmannin, a potent PI3K inhibitor, in unprecedented scientific depth—integrating mechanistic detail, new autophagy research, and expert guidance for cancer and apoptosis assay design. Discover how this cornerstone molecule from APExBIO empowers advanced signaling pathway studies.

450 records 17/30 page Previous Next First page 上5页 1617181920 下5页 Last page